These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 8196081

  • 1. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
    Schellens JH, Planting AS, van Acker BA, Loos WJ, de Boer-Dennert M, van der Burg ME, Koier I, Krediet RT, Stoter G, Verweij J.
    J Natl Cancer Inst; 1994 Jun 15; 86(12):906-12. PubMed ID: 8196081
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG).
    Aamdal S, Lund B, Koier I, Houten M, Wanders J, Verweij J.
    Cancer Chemother Pharmacol; 2000 Jun 15; 45(1):85-8. PubMed ID: 10647507
    [Abstract] [Full Text] [Related]

  • 4. Gradient high-performance liquid chromatographic assay for the determination of the novel indoloquinone antitumour agent E09 in biological specimens.
    Binger M, Workman P.
    J Chromatogr; 1990 Nov 16; 532(2):321-36. PubMed ID: 2084129
    [Abstract] [Full Text] [Related]

  • 5. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group.
    McLeod HL, Graham MA, Aamdal S, Setanoians A, Groot Y, Lund B.
    Eur J Cancer; 1996 Aug 16; 32A(9):1518-22. PubMed ID: 8911111
    [Abstract] [Full Text] [Related]

  • 6. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
    Hendriks HR, Pizao PE, Berger DP, Kooistra KL, Bibby MC, Boven E, Dreef-van der Meulen HC, Henrar RE, Fiebig HH, Double JA.
    Eur J Cancer; 1993 Aug 16; 29A(6):897-906. PubMed ID: 8484984
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
    Schellens JH, Dombernowsky P, Cassidy J, Epelbaum R, Dirix L, Cox EH, Wanders J, Calabresi F, Paridaens R, Monfardini S, Wolff J, Loos WJ, Verweij J, Pavlidis N, Hanauske AR, EORTC Early Clinical Studies Group.
    Anticancer Drugs; 2001 Aug 16; 12(7):583-90. PubMed ID: 11487714
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group.
    Dirix LY, Tonnesen F, Cassidy J, Epelbaum R, ten Bokkel Huinink WW, Pavlidis N, Sorio R, Gamucci T, Wolff I, Te Velde A, Lan J, Verweij J.
    Eur J Cancer; 1996 Oct 16; 32A(11):2019-22. PubMed ID: 8943690
    [Abstract] [Full Text] [Related]

  • 12. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
    Smitskamp-Wilms E, Hendriks HR, Peters GJ.
    Gen Pharmacol; 1996 Apr 16; 27(3):421-9. PubMed ID: 8723519
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
    Loadman PM, Phillips RM, Lim LE, Bibby MC.
    Biochem Pharmacol; 2000 Apr 01; 59(7):831-7. PubMed ID: 10718341
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I, Bench K, Beijnen JH, Bruntsch U, Cavalli F, de Jong J, Groot Y, van Tellingen O, Wanders J, Sessa C.
    Clin Cancer Res; 1996 Oct 01; 2(10):1717-23. PubMed ID: 9816122
    [Abstract] [Full Text] [Related]

  • 16. A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG).
    Pavlidis N, Hanauske AR, Gamucci T, Smyth J, Lehnert M, te Velde A, Lan J, Verweij J.
    Ann Oncol; 1996 Jul 01; 7(5):529-31. PubMed ID: 8839911
    [Abstract] [Full Text] [Related]

  • 17. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC, Whitfield LR, Grove WR, Rummel S, Grochow LB, Donehower RC.
    Clin Cancer Res; 2000 Oct 01; 6(10):3885-94. PubMed ID: 11051234
    [Abstract] [Full Text] [Related]

  • 18. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954.
    Chung-Faye G, Palmer D, Anderson D, Clark J, Downes M, Baddeley J, Hussain S, Murray PI, Searle P, Seymour L, Harris PA, Ferry D, Kerr DJ.
    Clin Cancer Res; 2001 Sep 01; 7(9):2662-8. PubMed ID: 11555577
    [Abstract] [Full Text] [Related]

  • 19. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
    Creemers GJ, Gerrits CJ, Eckardt JR, Schellens JH, Burris HA, Planting AS, Rodriguez GI, Loos WJ, Hudson I, Broom C, Verweij J, Von Hoff DD.
    J Clin Oncol; 1997 Mar 01; 15(3):1087-93. PubMed ID: 9060549
    [Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Kamiya Y, Saka H, Tanigawara Y, McGovren JP, Natsumeda Y.
    Cancer Chemother Pharmacol; 2006 Aug 01; 58(2):173-82. PubMed ID: 16308697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.